News Corporate Actions Shelter Pharma Board Approves Conversion of 2,79,000 Warrants into Equity SharesShelter Pharma Board Approves Conversion of 2,79,000 Warrants into Equity Shares
Shelter Pharma Limited successfully completed the conversion of 2,79,000 warrants into equity shares following board approval on March 07, 2026, raising ₹88.40 lakh from three non-promoter investors. The conversion increased the company's paid-up equity share capital from ₹16.33 crore to ₹16.61 crore, with the newly allotted shares ranking pari-passu with existing equity shares.
*this image is generated using AI for illustrative purposes only.
Shelter Pharma Limited has successfully completed the conversion of 2,79,000 warrants into equity shares, raising ₹88.40 lakh through the exercise of conversion rights by non-promoter warrant holders. The board of directors approved this conversion during their meeting held on March 07, 2026, as disclosed in the official regulatory filing to BSE Limited.
Board Meeting Outcome and Regulatory Compliance
The conversion was executed in accordance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The board meeting commenced at 12:15 PM and concluded at 12:45 PM, with the directors approving the allotment of 2,79,000 equity shares of face value ₹10.00 each upon warrant conversion.
| Parameter: | Details |
|---|---|
| Total Warrants Converted: | 2,79,000 |
| Exercise Price per Warrant: | ₹31.69 |
| Total Amount Raised: | ₹88.40 lakh |
| Face Value per Share: | ₹10.00 |
| Issue Price per Share: | ₹42.25 |
Investor Participation Details
Three non-promoter investors participated in the warrant conversion process with varying levels of participation. Rishabh Nayambhai Sharma converted 99,000 warrants out of his total holding of 5,40,000, having previously converted 2,01,000 warrants. Nayana Kamlesh Sheth fully converted her entire holding of 1,02,000 warrants, while Dipika Pankajbhai Patel converted 78,000 out of her 99,000 warrants.
| Investor: | Warrants Converted | Amount Paid (₹) | Outstanding Warrants |
|---|---|---|---|
| Rishabh Nayambhai Sharma: | 99,000 | 31.37 lakh | 2,40,000 |
| Nayana Kamlesh Sheth: | 1,02,000 | 32.32 lakh | 0 |
| Dipika Pankajbhai Patel: | 78,000 | 24.72 lakh | 21,000 |
Capital Structure Enhancement
The warrant conversion has resulted in a substantial increase in the company's paid-up equity share capital. The capital base expanded from ₹16.33 crore consisting of 1.63 crore equity shares to ₹16.61 crore comprising 1.66 crore equity shares, each with a face value of ₹10.00.
| Metric: | Before Conversion | After Conversion | Change |
|---|---|---|---|
| Paid-up Capital: | ₹16.33 crore | ₹16.61 crore | ₹0.28 crore |
| Total Equity Shares: | 1.63 crore | 1.66 crore | 2.79 lakh |
| Outstanding Warrants: | - | - | 2.61 lakh |
Background and Future Steps
The original warrant allotment of 88.08 lakh warrants was approved by shareholders at an extraordinary general meeting held on July 23, 2025, with BSE providing in-principle approval on July 22, 2025. The warrants were issued at ₹42.25 each with warrant holders paying 25% upfront and the remaining 75% upon conversion.
The newly allotted equity shares will rank pari-passu with existing equity shares in all respects, ensuring equal rights for all shareholders. The company will submit applications for listing and trading approval of the newly issued equity shares to the stock exchange in due course. The successful conversion demonstrates continued investor confidence in the company's growth prospects and provides additional capital for business operations.
Historical Stock Returns for Shelter Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.45% | -7.62% | -20.65% | -28.29% | -25.81% | -20.88% |
20
